Kliniska studier vid Tema Cancer

TailorDose II. TailorDose®-II: Therapeutic dose monitoring of commonly usedcytostatic drugs/regimes indicated for breast cancer

Oscar Wiklander

CAPItello-292. A Phase Ib/III Randomised Study of Capivasertib plusPalbociclib and Fulvestrant versus Placebo plus Palbociclib andFulvestrant in Hormone Receptor-Positive and HumanEpidermal Growth Factor Receptor 2-Negative LocallyAdvanced, Unresectable or Metastatic Breast Cancer

Theodoros Foukakis

CARDIOCARE. CARDIOCARE: AN INTERDISCIPLINARY APPROACH FOR THE MANAGEMENT OF THE ELDERLY MULTIMORBID PATIENT WITH BREAST CANCER THERAPY INDUCED CARDIAC TOXICITY

Andri Papakonstantinou

Neo-ACT. Physical exercise during neoadjuvant chemotherapy for breast cancer as a means to increase pathological complete response rates: the randomized Neo-ACT trial

Kristina Weibring

ARIADNE. A Randomized Trial on Biology-Driven De-escalation of Neoadjuvant Treatment for HER2-positive Breast Cancer

Alexios Matikas

PIPN. Paclitaxel-induced polyneuropathy in breast cancer: early detection, risk factors, quality of life and lifestyle outcomes

Theodoros Foukakis

Taormina. Treatment of Oligometastatic breast cancer – a randomised phase 3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1st line treatment

Kristina Weibring

Trofuse MK2870-010. An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Alexios Matikas

TREAT ctDNA . Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)

Theodoros Foukakis

Destiny Breast Respond HER2-low Europe. A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy

Theodoros Foukakis

C4391025 (FourLight-2). An Interventional, Open-Label, Randomized, Multicenter Phase 2 Study of PF- 07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older with Hormone Receptor-Positive, HER2-Negative Breast Cancer in the Neoadjuvant Setting

Theo Foukakis

Parafys. Primär hyperparathyroidism hos äldre – fysisk träning för att förbättra muskelfunktion, balans och kognitiv förmåga

Inga-Lena Nilsson

START-NET. Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine TumorsAn open-label, multi-center, randomized phase III controlled trial comparing safety and efficacy of trial comparing safety and efficacy of personalized vs non-personalized personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOC

David Goldstein

ADIUVO-2. Adjuvant mitotane vs. mitotane with cisplatin/etoposide after primary surgical resection of localised adrenocortical carcinoma with high risk of recurrence (ADIUVO-2 Trial): A pragmatic, randomised, low-intervention phase III, clinical trial with an observational arm.

David Goldstein

PREP. PREvention and Prediction of breast-and ovarian cancer - PREP

Angelique Flöter Rådestad

TUBA-WISP II. Tubectomy with delayed oophorectomy as alternative for risk reducing salpingo-oophorectomy in BRCA-women to assess the safety of prevention

Angelique Flöter Rådestad